- Algernon (AGN) has filed a Clinical Trials of Investigational Medicinal Products and Ethics Approval application with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
- The primary focus of the Phase 1 DMT study is to investigate prolonged intravenous infusion of DMT helping Algernon plan its Phase 2 study more effectively
- Christopher J. Moreau CEO of Algernon Pharmaceuticals sat down with Dave Jackson to discuss the news
- Algernon is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds, for new disease applications
- Algernon Pharmaceuticals Inc. (AGN) opened trading at C$11.15 per share
Algernon (AGN) has filed a Clinical Trials of Investigational Medicinal Products and Ethics Approval application with the UK MHRA.
This combined review service provides for a single application route for its planned Phase 1 clinical human study of AP-188 (“N,N-dimethyltryptamine” or “DMT”).
The company announced on November 19, 2021, that it had received positive feedback at a scientific advice meeting from the UK MHRA for its planned Phase 1 DMT Stroke study.
Christopher J. Moreau CEO of Algernon Pharmaceuticals sat down with Dave Jackson to discuss the news.
“This study will provide important information on dosage and duration of our new DMT IV formula to help us better plan for our Phase 2 study where we plan to test the drug with both acute and recovering stroke patients.”
The primary focus of the Phase 1 DMT study is to investigate prolonged intravenous infusion of DMT, for durations that have never been clinically studied. The resulting data generated will help Algernon plan both its Phase 2 acute stroke and rehabilitation studies more effectively.
N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug that produces effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.
Algernon Pharmaceuticals is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds.
Algernon Pharmaceuticals Inc. (AGN) opened trading at C$11.15 per share.
